Tuesday’s Biggest Winners and Losers in the S&P 500
Tuesday was a relatively flat day for the broad U.S. markets. The broad markets have been slowing down over the last few trading days as a result of increased strength in the bond markets.…
All Work
Chris Lange
Why PPG Shares Are Sliding
PPG Industries shares dropped on Tuesday after the company announced preliminary results for its third quarter. The expectations fell somewhat short, and inflation, as well as rising costs, are to blame for this.
Aurora Cannabis Gears Up for IPO
Aurora Cannabis, one of the world's largest and leading cannabis companies, has filed with the SEC in preparation for its initial public offering.
Can This New Board Member Help Save Sears?
Sears shares slid slightly after the company announced its newest addition to the board of directors, an advisor with experience in organizational change.
Mylan’s Mapi Collaboration for Multiple Sclerosis Doesn’t Seem to Be Paying Off
Mylan shares hit a 52-week low after Mapi Pharma announced midstage results from its multiple sclerosis trial.
Can This Clinical Hold Stop Affimed’s Momentum?
Affimed shares took a big step back early on Tuesday after the company announced that it has placed its AFM11 on clinical hold, and has notified the global health authorities of its decision.
Why This Activist Wants a Slice of Papa John’s
Papa John’s shares made a solid gain to kick off Tuesday after it was announced that an activist investor may be interested in the pizza chain.
Monday’s Biggest Winners and Losers in the S&P 500
Monday was a mixed day for the broad U.S. markets. At one point in the day, each of the major indices had a significant loss but each moved higher as the day went on.…
Akcea Stumbles Over Newest Board Addition
Akcea Therapeutics shares pulled back on Monday after the company announced a big change to its board of directors.
Exelixis Initiates Key Late-Stage Cancer Trial
Exelixis shares dipped on Monday after the company announced that it has initiated a late-stage trial in patients with radioiodine-refractory differentiated thyroid cancer (DTC).
Starbucks Announces Big Changes at the Top
Starbucks shares didn’t react much despite the coffee giant announcing a big change at the top. The company is appointing a new CFO who will be taking over at the end of November.
Wells Fargo, JPMorgan, Walgreens and More Major Earnings Coming This Week
A preview of Citigroup, Walgreens, Wells Fargo and some of the other major companies reporting their quarterly results this week.
Major Biopharma Catalysts to Watch For in October
Here 24/7 Wall St. includes a calendar of a few of the biggest companies expecting clinical trial and FDA updates in the remainder of October.
Friday’s Biggest Winners and Losers in the S&P 500
Friday was a down day for the broad U.S. markets, with each of the major indices notching a loss in the session. The Nasdaq again took the worst of the beating. Crude oil was…
Elastic Enters the Market With a Bang
Elastic, creator of Elastic Stack, entered the market with a bang on Friday. The company originally priced its shares at $36 apiece, but actually entered the market 93% higher at $69.50.
Does Snap’s Leaked Memo Signal a Turnaround?
Snap might be poised for a turnaround despite most of Wall Street betting against it. A recent leaked memo has CEO Evan Spiegel calling for break-even earnings in the fourth quarter and potential profitability…
KemPharm: The Secondary Offering From Hell
KemPharm shares were crushed on Friday after the company announced that it would be conducting a secondary offering.
SI-Bone Announces Potential Pricing for IPO
Medical device company SI-Bone intends to list 6 million shares in an initial public offering valued up to more than $103 million.
Costco Earnings Aren’t Enough for Investors
Costco released its fiscal fourth-quarter financial results after the markets closed on Thursday.
Thursday’s Biggest Winners and Losers in the S&P 500
Thursday was a down day for the broad U.S. markets, with each of the major indices notching a loss in the session. The Nasdaq took the worst of it seeing one of its worst…